Preliminary experience with paclitaxel (TAXOL®) plus recombinant human granulocyte colony-stimulating factor in the treatment of breast cancer Conference Paper
| Authors: | Seidman, A. D.; Norton, L.; Reichman, B. S.; Crown, J. P. A.; Yao, T. J.; Heelan, R.; Hakes, T. B.; Lebwohl, D. E.; Gilewski, T. A.; Surbone, A.; Currie, V.; Hudis, C. A.; Klecker, R.; Jamis-Dow, C.; Collins, J.; Quinlivan, S.; Berkery, R.; Toomasi, F.; Canetta, R.; Fisherman, J.; Arbuck, S. |
| Title: | Preliminary experience with paclitaxel (TAXOL®) plus recombinant human granulocyte colony-stimulating factor in the treatment of breast cancer |
| Conference Title: | Paclitaxel (TAXOL®) Investigators' Workshop |
| Abstract: | Single-agent paclitaxel (TAXOL®) was administered to 79 patients with stage IV breast cancer. Twenty-eight patients had no prior chemotherapy (for metastatic disease), and 51 patients had extensive exposure to other chemotherapeutic agents before beginning the 24-hour paclitaxel infusion. Routine use of recombinant human granulocyte colony-stimulating factor helped to ameliorate neutropenia, the dose-limiting toxicity, in some cases. Other toxicity was generally mild to moderate. Paclitaxel was more active in patients whose stage IV disease had not yet been exposed to chemotherapy, but activity was seen in the patients previously treated extensively as well. There is a strong clinical suggestion of non-cross-resistance with doxorubicin. In one case, an excellent response in previously irradiated skin was seen. Paclitaxel is a very promising agent for the treatment of metastatic breast cancer. |
| Keywords: | adult; treatment outcome; aged; major clinical study; neutropenia; salvage therapy; doxorubicin; cancer combination chemotherapy; dose response; drug efficacy; multimodality cancer therapy; conference paper; paclitaxel; breast cancer; bone marrow suppression; blood toxicity; mucosa inflammation; thrombocytopenia; antineoplastic combined chemotherapy protocols; myalgia; peripheral neuropathy; breast neoplasms; arthralgia; recombinant proteins; neoplasm metastasis; phase 1 clinical trial; taxane derivative; granulocyte colony-stimulating factor; recombinant granulocyte macrophage colony stimulating factor; intravenous drug administration; middle age; cremophor; human; female; priority journal; support, u.s. gov't, p.h.s. |
| Journal Title | Seminars in Oncology |
| Volume: | 20 |
| Issue: | 4 Suppl. 3 |
| Conference Dates: | 1992 Sep 25 |
| Conference Location: | Baltimore, MD |
| ISBN: | 0093-7754 |
| Publisher: | Elsevier Inc. |
| Date Published: | 1993-08-01 |
| Start Page: | 40 |
| End Page: | 45 |
| Language: | English |
| PUBMED: | 7688145 |
| PROVIDER: | scopus |
| DOI/URL: | |
| Notes: | Conference Paper -- Export Date: 1 March 2019 -- Source: Scopus |
